The fourth generation EGFR inhibitor!

ArticleMedicine Guanlan

On December 5, Betta Pharmaceuticals issued a press release stating that it has received a new drug clinical trial approval notice issued by the US FDA, agreeing to its fourth-generation EGFR inhibitor BPI-361175 tablets for the treatment of EGFR C797S mutations and others Drug clinical trial application for non-small cell lung cancer with EGFR-related mutations

As we all know, the morbidity and mortality of lung cancer remain high regardless of whether it is in the world or in China

According to the press release, BPI-361175 is a new molecular entity compound independently developed by Betta Pharmaceuticals.

Preclinical data shows that BPI-361175 has the same biological activity in vivo and in vitro, can effectively inhibit the proliferation of tumor cells carrying EGFR C797S mutations, and has shown good anti-tumor effects on multiple xenograft tumor models carrying EGFR-related mutations

The press release also pointed out that the current domestic and foreign drugs that carry the EGFR C797S mutation are in the preclinical or early clinical stage, and no drugs are on the market

Reference materials:

[1] Beida Pharmaceuticals' fourth-generation EGFR inhibitor BPI-361175 was approved for clinical use in the U.

[2] Beida Pharmaceuticals' fourth-generation EGFR inhibitor BPI-361175 was approved for clinical trials.